MedCity News

Capital Rx Expands Into Care Navigation with Acquisition of Amino Health

Bristol Myers Squibb Is Paying $350M to Expand Its Reach in Radiopharmaceuticals to Prostate Cancer

Bristol Myers Squibb is licensing global rights to a Philochem program in development for both diagnostic imaging and targeted treatment of prostate cancer. It follows the pharma giant’s entry into radiopharmaceuticals via the $4.1 billion acquisition of RayzeBio last year.

By Frank Vinluan

Policy

‘We Dissent’: NIH Workers Protest Trump Policies That ‘Harm the Health of Americans’

The letter is an extraordinary rebuke of the Trump administration’s actions against the NIH, which include: terminating hundreds of grants funding scientific and biomedical research; firing more than 1,000 employees this year; and moving to end billions in funds to partner institutions overseas.

By Rachana Pradhan

MedCity Influencers

Managing Routine Radiology: An Opportunity to Control Costs and Improve Care

Managing routine radiology does not require the administrative burden of prior authorization. Instead, health plans can implement post-service, pre-payment automated management based on clinical guidelines.

By Jim Koger and Mark Hiatt

Latest News

Healthcare’s Provider Data Challenges

Provider data issues start at enrollment and continue throughout the provider lifecycle, impacting everything from credentialing to the provider directory. ProviderTrust's new guide explores this topic.

By Stephanie Baum

Health Tech

Lucet to Acquire Home Care Company Emcara Health

Lucet, a behavioral health company, is acquiring home care company Emcara Health to offer integrated care models.

By Marissa Plescia

Providers, Hospitals, Policy

The GOP’s Budget Plan Is a Crisis in the Making for Hospitals

If enacted, the GOP’s spending bill could kick more than 10 million Americans off Medicaid. Experts are worried about the major spike in uncompensated care that hospitals would have to provide — and they’re warning that this change will result in major revenue losses for hospitals, facility closures, higher premiums for commercially insured patients, and worse public health.

By Katie Adams

BioPharma, Pharma

Following Novo Nordisk, Eli Lilly Lands Partner for R&D of Longer-Acting Metabolic Meds

Eli Lilly is partnering with Camurus, a company with technology that extends how long an injectable drug lasts in the body, permitting longer dosing intervals. Lilly plans to apply the technology to its metabolic medicines; the deal follows a similar move Novo Nordisk starting an alliance with Ascendis.

By Frank Vinluan

MedCity Influencers

The Connected Patient Experience: 3 Tips to Empower Healthcare Delivery Through Innovation

Patients no longer want to rely upon only whatever snippets of information they get from their doctor at an annual or semiannual checkup. They’re looking for a fully connected patient experience. Healthcare organizations need to know what that looks like, how to build it, and how they fit into the full picture.

By Luiz Cieslak

MedCity Influencers

The National Security Stakes of Pharmaceutical Tariffs

Healthcare supplies have a direct correlation to the safety and national security of Americans as any disruption to availability jeopardizes the health of our nation. Americans cannot forego access to lifesaving medications.

By Soumi Saha and Mark Hendrickson

Events

Navigating the AI in Healthcare Landscape and Its Future: A Preview of INVEST Digital Health 2025

MedCity INVEST Digital Health on September 18 at Pegasus Park in Dallas will explore AI through a series of discussions leading up to our annual Pitch Perfect contest, where healthcare startups pitch their companies to a team of investor judges. Register today!

By Stephanie Baum

BioPharma, Pharma

Kura Oncology Drug’s Data at ASCO Support FDA Filing Now Under Priority Review for Leukemia

Kura Oncology’s ziftomenib addresses a specific genetic mutation present in about 30% of cases of acute myeloid leukemia. Data from the drug’s pivotal Phase 2 test were presented during the annual meeting of the American Society of Clinical Oncology.

By Frank Vinluan

Health Tech

Pyx Health Acquires FarmboxRx With $47.5M Funding Boost

Acquiring FarmboxRx will help Pyx Health tackle food insecurity, a challenge many of its members struggle with.

By Marissa Plescia

MedCity Influencers

Weathering the Shifting Trial Landscape

This is the moment to build flexible plans. Organizations that develop operational models with built-in scenario planning, ready to scale up or down as the capital environment shifts, will be positioned to take advantage of greater investment when it comes.

By Tony Proctor and Abdul Rastagar

MedCity Influencers

The Age of Action: Seizing CMS’s Call to Reimagine Medicare

The combination of coverage awareness and care navigation powered by agentic AI has the potential to transform how older adults engage with the healthcare system.

By Karl Ulfers

BioPharma, Pharma

BMS Buys Into BioNTech Bispecific Antibody, Putting Up $1.5B to Collaborate in Multiple Cancers

Bristol Myers Squibb’s partnership with BioNTech makes it the third big pharma company to strike a deal to gain access to a PD-L1/PD-1 and VEGF bispecific antibody with potential use in drug combinations to treat cancer. The deal calls for the two companies to share in the development of BioNTech’s drug and co-commercialize the asset globally.

By Frank Vinluan

Startups

How One Startup Is Aiming to Replace Surgery with Its Endometriosis Diagnostic

Heranova Lifesciences recently launched a noninvasive blood test to diagnose endometriosis. The standard diagnostic method is laparoscopy, which requires anesthesia, followed by histological confirmation. With its blood test, Heranova seeks to replace the diagnostic function of laparoscopy, thus reserving surgical intervention only for therapeutic purposes.

By Katie Adams